Lilly(Eli) & Co
Lilly(Eli) & Co (LLY) Option Chain
As of October 26, 2026, Lilly(Eli) & Co is trading at $1,279.14, a +0.45% change from the previous close. The nearest expiration is Oct 30, 2026. Implied volatility is 40.4%. IV Rank is 72%.
Read more
Tracking the LLY option chain helps you see every strike and expiry on Lilly(Eli) & Co in one view, so you can quickly identify the contracts that fit your thesis and your risk. Lilly(Eli) & Co's option chain lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of LLY options activity at a glance. Use our scanner to monitor the LLY option chain in real time and filter for the LLY options trades that actually meet your criteria.
An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For LLY stock options, the chain shows side-by-side call and put data, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading the LLY option chain effectively means looking beyond the last price — implied volatility by strike, volume-to-open-interest ratios, and bid-ask spreads all tell you where LLY stock options are being actively traded and where they are not.
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer.
It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Credit spreads, long calls, iron condors, calendar trades — every strategy starts with the same raw material: a clean, complete option chain. Our scanner pulls Lilly(Eli) & Co's full chain across every expiry, highlights the most liquid strikes, and lets you screen LLY options by the metrics that matter, from IV skew to volume surges. Stop scrolling through endless rows of LLY stock options — let the full option chain come to you, pre-filtered and ready to trade.
Stock Statistics
- IndustryDrug Manufacturers - General
- SectorHealthcare
- IV percentile85.32% Elevated
- Market cap (M$)1,204,131
- 52 weeks high-3.18%
- 52 weeks low57.99%
- Analyst recommendationStrong Buy
1.48 - Target price$1,370.46
7.14% above the current stock price - Dividend—
- Payout ratio26.14%
- Earnings date2026-10-29
- P/E43.47
- Future P/E26.95
- EPS (ttm)29.43
- EPS growth next 5 years30.93%
As of October 26, 2026
| CALLs | PUTs | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prob. OTM % | Open Interest | Volume | Extrinsic Value | Intrinsic Value | Bid | Ask | Strike | Moneyness % | Bid | Ask | Intrinsic Value | Extrinsic Value | Volume | Open Interest | Prob. OTM % |
| 51.44 | 70 | 19 | 36.61 | 4.14 | 37.00 | 44.50 | 1,275.00 | +0.12 | 36.95 | 48.60 | 0.00 | 42.78 | 55 | 16 | 48.56 |
| 52.94 | 0 | 17 | 38.31 | 1.64 | 37.90 | 42.00 | 1,277.50 | +0.32 | 39.05 | 47.55 | 0.00 | 43.30 | 1 | 6 | 47.06 |
| 54.43 | 199 | 82 | 38.50 | 0.00 | 36.35 | 40.65 | 1,280.00 | +0.51 | 38.45 | 50.30 | 0.86 | 43.52 | 29 | 87 | 45.57 |
| 55.91 | 2 | 7 | 37.03 | 0.00 | 32.05 | 42.00 | 1,282.50 | +0.71 | 40.55 | 53.20 | 3.36 | 43.52 | 31 | 2 | 44.09 |
| 57.38 | 30 | 21 | 35.35 | 0.00 | 31.55 | 39.15 | 1,285.00 | +0.91 | 41.85 | 51.55 | 5.86 | 40.84 | 11 | 12 | 42.63 |
As of October 26, 2026
Scan the full option chain in one place
Browse the full LLY option chain across every strike and expiration, filter by IV, volume, and open interest, and evaluate your trade without switching tools.
Start your 14-day free trial→